FOXP3 and vulva cancer: Although they partly differ in their study design (evaluation of tissue-micro arrays vs. whole slide analysis or different immunohistochemical markers put to test), the vast majority of them did not report an influence of certain (sub-)populations of lymphocytes with regard to prognosis [27–30]: De Jong et al. did not determine an association of CD8 + T-lymphocytes and Foxp3 + T-lymphocytes with regard to survival when examining specimens of 286 patients with vulvar cancer [27].